These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 29504279

  • 1. Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.
    Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A.
    J Diabetes Investig; 2018 Mar; 9(2):448-449. PubMed ID: 29504279
    [Abstract] [Full Text] [Related]

  • 2. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy.
    Okamoto M, Okamoto M, Gotoh K, Masaki T, Ozeki Y, Ando H, Anai M, Sato A, Yoshida Y, Ueda S, Kakuma T, Shibata H.
    J Diabetes Investig; 2016 Nov; 7(6):915-918. PubMed ID: 27181090
    [Abstract] [Full Text] [Related]

  • 3. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
    Miyoshi Y, Ogawa O, Oyama Y.
    Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
    [Abstract] [Full Text] [Related]

  • 4. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
    Matsumura K, Nagasawa K, Oshima Y, Kikuno S, Hayashi K, Nishimura A, Okubo M, Uruga H, Kishi K, Kobayashi T, Mori Y.
    J Diabetes Investig; 2018 Mar; 9(2):438-441. PubMed ID: 28418115
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
    Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L, Madelaine-Chambrin I, Bagot M, Basset-Seguin N, Pages C, Mourah S, Boudou P, Lebbé C, Gautier JF.
    Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
    [Abstract] [Full Text] [Related]

  • 7. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study.
    Gauci ML, Boudou P, Baroudjian B, Vidal-Trecan T, Da Meda L, Madelaine-Chambrin I, Basset-Seguin N, Bagot M, Pages C, Mourah S, Resche-Rigon M, Pinel S, Sassier M, Rouby F, Eftekhari P, Lebbé C, Gautier JF.
    Cancer Immunol Immunother; 2018 Aug; 67(8):1197-1208. PubMed ID: 29808365
    [Abstract] [Full Text] [Related]

  • 8. Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.
    Shiba M, Inaba H, Ariyasu H, Kawai S, Inagaki Y, Matsuno S, Iwakura H, Yamamoto Y, Nishi M, Akamizu T.
    Intern Med; 2018 Jul 15; 57(14):2029-2034. PubMed ID: 29491310
    [Abstract] [Full Text] [Related]

  • 9. A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.
    Yamamoto N, Tsurutani Y, Katsuragawa S, Kubo H, Sunouchi T, Hirose R, Hoshino Y, Ichikawa M, Takiguchi T, Yukawa H, Arioka H, Saitou J, Nishikawa T.
    Intern Med; 2019 Oct 01; 58(19):2825-2830. PubMed ID: 31243198
    [Abstract] [Full Text] [Related]

  • 10. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 11. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan 01; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 12. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.
    Munakata W, Ohashi K, Yamauchi N, Tobinai K.
    Int J Hematol; 2017 Mar 01; 105(3):383-386. PubMed ID: 27696192
    [Abstract] [Full Text] [Related]

  • 13. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Mar 01; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 14. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M.
    Expert Rev Anticancer Ther; 2015 Mar 01; 15(9):981-93. PubMed ID: 26313415
    [Abstract] [Full Text] [Related]

  • 15. A case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient.
    Araújo M, Ligeiro D, Costa L, Marques F, Trindade H, Correia JM, Fonseca C.
    Immunotherapy; 2017 Jun 01; 9(7):531-535. PubMed ID: 28595520
    [Abstract] [Full Text] [Related]

  • 16. Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.
    Jehl A, Cugnet-Anceau C, Vigouroux C, Legeay AL, Dalle S, Harou O, Marchand L, Lascols O, Caussy C, Thivolet C, Laville M, Disse E.
    Diabetes Care; 2019 Oct 01; 42(10):2008-2010. PubMed ID: 31434650
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
    Marchand L, Reffet S, Dalle S, Disse E, Vouillarmet J, Cugnet-Anceau C, Thivolet C.
    Acta Diabetol; 2019 Mar 01; 56(3):377-378. PubMed ID: 30506459
    [No Abstract] [Full Text] [Related]

  • 20. The role of nivolumab in melanoma.
    Gomes F, Serra-Bellver P, Lorigan P.
    Future Oncol; 2018 Jun 01; 14(13):1241-1252. PubMed ID: 29328782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.